Goodrx Holdings, INC Form 4 insider transactions

Julie Bradley, a director at GoodRx Holdings, reported acquiring 2,464 shares of Class A common stock on July 8, 2024.

Director Ian T Clark reports acquisition of 25,852 shares of Class A Common Stock and 51,745 Restricted Stock Units.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Douglas Joseph Hirsch, Chief Mission Officer of GoodRx Holdings, Inc., transferred shares of Class A Common Stock to two Grantor Retained Annuity Trusts (GRATs) in transactions dated June 7 and June 10, 2024.

Trevor Bezdek, Chairman of GoodRx Holdings, reports the transfer of Class A Common Stock to Grantor Retained Annuity Trusts (GRATs) and a transfer by his spouse.

Julie Bradley, a director at GoodRx Holdings, reported acquiring 28,398 shares of Class A Common Stock on June 6, 2024.

Kelly J. Kennedy, a director of GoodRx Holdings, Inc., reported acquiring 28,398 shares of Class A common stock on June 6, 2024, through restricted stock units.

Agnes Rey-Giraud, a director of GoodRx Holdings, Inc., acquired 28,398 deferred stock units on June 6, 2024, according to a recent SEC filing.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.

Karsten Voermann, CFO of GoodRx Holdings, Inc., reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

Douglas Joseph Hirsch, Chief Mission Officer at GoodRx Holdings, reported the acquisition and disposal of Class A and Class B common stock on June 1, 2024.

Trevor Bezdek, Chairman of GoodRx Holdings, reports the vesting and conversion of restricted stock units and Class B common stock into Class A common stock.

Scott Wagner, Interim CEO of GoodRx Holdings, reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units on May 8, 2024.

Chief Accounting Officer of GoodRx Holdings, Romin Nabiey, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and disposal of restricted stock units and shares of Class A common stock.

Scott Wagner, Interim CEO of GoodRx Holdings, reports acquisition of restricted stock units and stock options.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the acquisition of restricted stock units and stock options.

Karsten Voermann, CFO of GoodRx Holdings, Inc., reports the acquisition of restricted stock units and stock options, increasing his beneficial ownership in the company.

Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, reports the vesting and subsequent disposal of Class A Common Stock to cover tax obligations.

Karsten Voermann, CFO of GoodRx Holdings, Inc., reported the vesting and subsequent disposal of shares related to restricted stock units on March 8, 2024.

GoodRx Holdings will repurchase shares from Spectrum Equity VII, L.P., Spectrum VII Investment Managers' Fund, L.P., and Spectrum VII Co-Investment Fund L.P. for approximately $44.9 million.

GoodRx Holdings will repurchase 14,622,366 shares of Class A Common Stock from Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. for approximately $105.1 million.

Douglas Joseph Hirsch, Chief Mission Officer at GoodRx Holdings, reports the conversion and disposal of Class B Common Stock and acquisition of Class A Common Stock on March 1, 2024.

Trevor Bezdek, Chairman of GoodRx Holdings, reports the conversion and disposal of Class B Common Stock into Class A Common Stock, along with related transactions.